Document 1093
 DOCN  M94A1093
 TI    Human leukocyte alpha-interferon in cream for the treatment of genital
       herpes. A placebo-controlled, double-blind study.
 DT    9412
 AU    Syed TA; Lundin S; Kahlon BM; Ahmad SA; Kahlon RC; Dept. of Clinical
       Physiology, University Hospital Malmo,; University of Lund, Sweden.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):210 (abstract no. PB0852). Unique
       Identifier : AIDSLINE ICA10/94371482
 AB    OBJECTIVE: The study was conducted to evaluate the clinical efficacy of
       human leukocyte alpha-interferon in cream containing 2 x 10(6) IU/g to
       cure patients afflicted with first episodes of genital herpes. METHODS:
       Patients (n = 60) aged 18-40 years (mean 22.8 years) with culture-proven
       herpes simplex genitalis, harboring 752 lesions (mean 12.3 number) were
       randomly allocated into two parallel groups, (active/placebo). Each
       patient received a 40 g tube with instructions to apply the test
       medication on their lesions thrice daily for five consecutive days,
       (max. 15 topical applications per week). Study was scheduled for 16
       weeks, with (4 weeks active treatment). Patients were examined on weekly
       basis. A completely re-epitheliazed lesion with persistent erythema was
       evaluated as healed or cured. RESULTS: Leukocyte alpha-interferon cream
       treated patients had significantly shorter mean duration of viral
       shedding/healing than placebo recipients, 7 days vs. 15 days (p < 0.01),
       and so the number of cured patients, 24/30 (80%) vs. 5/30 (17%) p <
       0.001, with no complaint of adverse symptoms. CONCLUSION: Leukocyte
       alpha-interferon (2 x 10(6) IU/g) in hydrophilic cream is more
       efficacious than placebo and can be considered a home-based reliable
       treatment to cure genital herpes in males.
 DE    Administration, Topical  Adolescence  Adult  Double-Blind Method  Herpes
       Genitalis/*DRUG THERAPY  Human  Interferon-alpha/*ADMINISTRATION &
       DOSAGE  Ointments  CLINICAL TRIAL  MEETING ABSTRACT  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).